证券代码：301087 证券简称：可孚医疗 公告编号：2026-032 可孚医疗科技股份有限公司 关于取得医疗器械注册证的公告 | 产品名称 | 注册证编号 | 注册证 | 注册 | 预期用途 | | --- | --- | --- | --- | --- | | | | 有效期 | 分类 | 本产品用于体外定性检测人粪便中的幽门 | | 幽门螺杆菌 | | | | 螺杆菌（Helicobacter pylori，简称 HP）抗 | | 抗原检测试 | 国械注准 | 2026.3.27 | | 原。本产品用于幽门螺杆菌感染的辅助诊 | | 剂盒（胶体 | 20263400632 | 至 | Ⅲ类 | 断，适合专业医疗单位用于粪便样本中幽门 | | 金法） | | 2031.3.26 | | 螺杆菌抗原检测，也适合消费者家庭自测， | | | | | | 不建议用于幽门螺杆菌根除治疗后人群进 | | | | | | 行自测。 | 幽门螺杆菌抗原检测试剂盒（胶体金法）采用胶体金免疫层析技术，定性检 测人粪便样本是否含有幽门螺杆菌抗原，适用于医疗机构及居家自测等场景， 10-20 分钟即可完成检测，操作便捷、结果判 ...

特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 可孚医疗科技股份有限公司（以下简称"公司"）正在进行申请发行境外上 市外资股（H 股）并在香港联合交易所有限公司（以下简称"香港联交所"）主 板挂牌上市（以下简称"本次发行上市"）的相关工作。香港联交所上市委员会 于 2026 年 3 月 26 日举行上市聆讯，审议公司本次发行上市的申请。 公司本次发行上市的联席保荐人已于 2026 年 3 月 27 日收到香港联交所向其 发出的信函，其中指出香港联交所上市委员会已审阅公司的上市申请，但该信函 不构成正式的上市批准，香港联交所仍有对公司的上市申请提出进一步意见的权 力。 公司本次发行上市尚需取得香港证券及期货事务监察委员会和香港联交所 等相关政府机关、监管机构的核准和/或批准，该事项仍存在不确定性。公司将 根据该事项的进展情况依法及时履行信息披露义务，敬请广大投资者注意投资风 险。 证券代码：301087 证券简称：可孚医疗 公告编号：2026-033 可孚医疗科技股份有限公司 关于香港联交所审议公司发行H股的公告 可孚医疗科技股份有限公司董事会 20 ...

证券代码：301087 证券简称：可孚医疗 公告编号：2026-031 可孚医疗科技股份有限公司 2025年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东会未出现否决议案的情形。 2. 本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1. 会议召开时间： 4. 会议召集人：公司董事会。 5. 会议主持人：董事长张敏先生。 6. 会议出席情况： （1）股东出席会议的总体情况 （1）现场会议时间：2026 年 3 月 31 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 3 月 31 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为 2026 年 3 月 31 日 9:15 至 15:00 的任意时间。 2. 现场会议召开地点：长沙市雨花区万家丽中路一段 426 号高桥大健康医 药城 8 楼 801 会议室。 3. 会议召开方式：采取现场投票与网络投票相结合的方式。 通过现场 ...

湖南启元律师事务所 关于 可孚医疗科技股份有限公司 2025年年度股东会的 法律意见书 二零二六年三月 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 电话：0731-82953778 传真：0731-82953779 邮编：410000 网站：www.qiyuan.com 致：可孚医疗科技股份有限公司 湖南启元律师事务所（以下简称"本所"）接受可孚医疗科技股份有限公司（以 下简称"公司"）的委托，指派本所律师出席了公司 2025 年年度股东会（以下简称 "本次股东会"），对本次股东会的召集和召开程序、出席会议人员及召集人的资 格、表决程序和表决结果的合法有效性进行现场律师见证，并发表本法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以 下简称"《股东会规则》"）等我国现行法律法规、规范性文件以及《可孚医疗科 技股份有限公司章程》（以下简称"《公司章程》"）的有关规定出具本法律意见 书。 本所律师声明如下： （二）本所律师出具本法律意见是基于公司已承诺所有提供给本所律师的文 件的正本以及经 ...

Group 1: Performance Overview - The company will disclose its Q1 2026 report on April 24, 2026, and investors are advised to refer to this report for specific performance details [2]. Group 2: Respiratory Device Business Development - The smart connected ventilator has maintained rapid growth since its launch, ranking among the top categories on major e-commerce platforms [2]. - The company launched the C11 smart ventilator in March 2026, featuring a patented multi-level acoustic optimization structure that reduces operational noise to 23 decibels without traditional sound-absorbing materials [2]. - The C11 integrates a cloud-based large language model and intelligent sensing algorithms to automatically compensate for issues like patient repositioning, air leakage, or rapid breathing, while providing users with sleep health insights and personalized recommendations via an app [2]. Group 3: Future Plans - The company aims to continue deepening its focus on respiratory health, steadily advancing product iterations, and enhancing the integration of artificial intelligence with respiratory devices [2]. - Plans include accelerating overseas product certification and channel establishment to boost the international market presence of ventilators [2]. - The company is committed to expanding its global footprint and continuously improving product competitiveness [2].

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [1] Core Insights - The pharmaceutical sector has shown resilience, with the innovative drug segment leading a rebound, driven by positive industry dynamics and market sentiment [7][10] - The report emphasizes the potential for continued growth in innovative drugs, supported by favorable government policies and strong performance in recent financial disclosures from biotech and biopharma companies [7][10] - The long-term care insurance (LTCI) policy in China is expected to accelerate the development of the elderly care industry, drawing parallels with Japan's successful model [10][23] Summary by Sections 1. Long-term Care Insurance and Elderly Care Industry - The Chinese government aims to establish a long-term care insurance system within three years, initially covering employees, retirees, and gradually including unemployed rural residents [10] - The LTCI system is designed to alleviate the financial burden on families and improve care for the elderly, with a focus on home and community care [10][23] - Investment opportunities in the elderly care sector include home medical devices, rehabilitation equipment, and elderly care institutions [23] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical index increased by 1.56% during the week of March 23-27, outperforming the ChiNext and CSI 300 indices [24] - The overall trading volume for pharmaceuticals was 449.11 billion yuan, accounting for 4.28% of the total market, below the historical average of 7.06% [46] - The report highlights the strong performance of innovative drugs, with companies like Meinuohua and Wanbangde leading the gains [49] 3. Investment Recommendations - The report suggests focusing on companies involved in the overseas big pharma BD 2.0 phase, such as Kelun Pharmaceutical and Xinlitai, as well as small and mid-cap biotech firms with innovative technologies [7][23] - It also recommends monitoring the supply chain and technology sectors, including CROs and CDMOs, as they are expected to benefit from ongoing industry trends [7][23]

Core Viewpoint - Multiple listed companies have announced substantial cash dividends for the fiscal year 2025, reflecting strong financial performance and a commitment to returning value to shareholders [2][3][4]. Financial Performance Summary - Farah Electronics reported a revenue of 5.327 billion yuan, an increase of 11.64% year-on-year, and a net profit of 1.192 billion yuan, up 14.72% [2]. - The company plans to distribute a cash dividend of 23 yuan per 10 shares, totaling 517.5 million yuan, which represents 43.41% of its net profit [2]. - Xinhua Insurance plans to distribute a cash dividend of 2.06 yuan per share, totaling 6.426 billion yuan, based on a total share count of 3.1195 billion [3]. - New Hope Co. intends to distribute 9.60 yuan per 10 shares, amounting to 2.97 billion yuan [4]. - Transsion Holdings will distribute 9.00 yuan per 10 shares, totaling 1.036 billion yuan, which is 40.15% of its net profit [4]. Dividend Distribution Plans - Jiepte plans to distribute 8.90 yuan per 10 shares, totaling approximately 84.37 million yuan, which is 30.26% of its net profit [4]. - Hualan Biological plans to distribute 8.00 yuan per 10 shares, totaling 476 million yuan [4]. - Donghang Logistics will distribute 6.77 yuan per 10 shares, totaling 1.075 billion yuan, which is 40% of its net profit [5]. - Jiangling Motors plans to distribute 5.5581 yuan per 10 shares, totaling 475 million yuan [7]. - Huazhong Heavy Industry plans to distribute 5.12 yuan per 10 shares, totaling 599 million yuan [8]. Additional Companies Announcing Dividends - Jingwang Electronics plans to distribute 5.50 yuan per 10 shares [8]. - China Southern Airlines plans to distribute 5.10 yuan per 10 shares, totaling 544 million yuan, which is 58.76% of its net profit [8]. - Galaxy Magnetics plans to distribute 4.00 yuan per 10 shares, totaling 129 million yuan [9]. - Xidian New Energy plans to distribute 4.00 yuan per 10 shares [9].

- Model Name: 250-Day New High Distance Model; Model Construction Idea: The model tracks the distance of the latest closing price from the highest closing price in the past 250 trading days to identify stocks that are hitting new highs; Model Construction Process: The formula used is $ 250 \text{ Day New High Distance} = 1 - \frac{Closet}{ts\_max(Close, 250)} $ where Closet is the latest closing price and ts_max(Close, 250) is the maximum closing price in the past 250 trading days. If the latest closing price hits a new high, the distance is 0; if it falls back, the distance is positive, indicating the extent of the fallback[11][12][13]; Model Evaluation: This model is effective in identifying stocks that are leading the market and can be used to track market trends and hotspots[11][19] - Factor Name: Stable New High Stocks; Factor Construction Idea: The factor focuses on stocks that have not only hit new highs but also exhibit stable price paths and strong momentum; Factor Construction Process: The selection criteria include analyst attention (at least 5 buy or hold ratings in the past 3 months), relative stock strength (top 20% in market performance over the past 250 days), price stability (using metrics like the sum of absolute daily returns over the past 120 days), and trend continuation (average 250-day new high distance over the past 120 days and past 5 days). The top 50% of stocks based on these criteria are selected[26][29][30]; Factor Evaluation: This factor is designed to capture stocks with strong and stable momentum, which are less likely to experience sudden drops and more likely to continue their upward trend[26][29] Model Backtest Results - 250-Day New High Distance Model, Shanghai Composite Index: 6.43%, Shenzhen Component Index: 5.13%, CSI 300: 6.01%, CSI 500: 10.64%, CSI 1000: 9.51%, CSI 2000: 9.52%, ChiNext Index: 2.73%, STAR 50 Index: 16.40%[12][34] Factor Backtest Results - Stable New High Stocks, Number of Stocks: 14, including companies like Asia Integration, Biwin Storage, Salt Lake Shares, etc.; Sector Distribution: Most stocks are from cyclical and technology sectors, with 6 stocks each. In the cyclical sector, the most new highs are in the basic chemical industry; in the technology sector, the most new highs are in the electronics industry[30][33]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 可孚医疗科技股份有限公司（以下简称"公司"）已于 2026 年 3 月 10 日在 巨潮资讯网（www.cninfo.com.cn）披露 2025 年年度报告全文及其摘要。 为便于广大投资者进一步了解公司 2025 年度经营情况，公司定于 2026 年 3 月 30 日（星期一）15:00-17:00 举办 2025 年度网上业绩说明会。本次年度业绩 说明会将采用网络远程的方式举行，投资者可登录深圳证券交易所"互动易"平台 （http://irm.cninfo.com.cn）进入"云访谈"栏目参与本次年度业绩说明会。 证券代码：301087 证券简称：可孚医疗 公告编号：2026-030 出席本次业绩说明会的人员有：公司董事长、总裁张敏先生，董事、副总裁、 董事会秘书薛小桥先生，独立董事宁华波先生，副总裁兼财务总监陈望朋先生（如 遇特殊情况，参会人员可能进行调整）。 可孚医疗科技股份有限公司 关于举行2025年度网上业绩说明会的公告 特此公告。 为充分尊重投资者、提升交流的针对性，现就公司本次业绩说明会提前向投 ...

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2] Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index declining by 4.8% from March 13 to March 20, 2026, which is 0.7 percentage points worse than the Shenwan A Index [4][5] - Upcoming earnings reports from key companies such as Lin Qingxuan and Shangmei will be critical to monitor [4][10] - The report highlights the performance of major companies, noting that Aimeike's revenue for 2025 is projected at 2.453 billion yuan, a year-on-year decrease of 18.94% [11] Summary by Sections Industry Performance - The Shenwan Cosmetics Index fell by 3.4%, while the Shenwan Personal Care Index dropped by 4.4%, indicating varied performance within the sector [4][5] - The report notes that the beauty care sector is entering earnings season, with several companies set to announce their financial results [10] Company Highlights - Aimeike's 2025 performance shows a revenue of 2.453 billion yuan, down 18.94% year-on-year, with a net profit of 1.291 billion yuan, down 34.05% [11] - Juzi Biotechnology reported a slight revenue decline of 0.4% to 5.519 billion yuan, with a net profit decrease of 7.2% [11] - The report emphasizes the importance of product matrix improvement and collaboration for growth in Aimeike's future performance [12] Market Trends - The report indicates that the retail sales of cosmetics in China grew by 4.5% year-on-year in the first two months of 2026, outperforming overall retail growth [16] - The report also notes that the domestic market is seeing a shift towards local brands, with significant growth in market share for domestic products [23] Industry Dynamics - The report discusses the strategic partnership between L'Oréal and NVIDIA to enhance AI research in beauty products, reflecting a trend towards technological integration in the industry [20] - The competitive landscape is evolving, with domestic brands gaining ground against international players, particularly in the skincare segment [23]